- Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy
- Rusfertide was associated with lower disease-related symptoms in patients with moderate/severe scores at baseline as assessed by the Myeloproliferative Neoplasm Symptom Assessment Form
- REVIVE is one of two pivotal studies, including an ongoing Phase 3 study, VERIFY, which is nearing enrollment completion
NEWARK, CA / ACCESSWIRE / February 21, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced publication in the New England Journal of Medicine (NEJM) of the REVIVE Phase 2 study (NCT04057040) results evaluating the efficacy and safety of rusfertide in polycythemia vera (PV), a myeloproliferative neoplasm affecting approximately 160,000 patients in the United States (US). Rusfertide, a peptide mimetic of the natural hormone hepcidin, represents a novel erythrocytosis-specific approach for the potential treatment of PV.
The study demonstrated that rusfertide controlled erythrocytosis, maintained hematocrit levels